{
    "clinical_study": {
        "@rank": "119555", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give Viracept plus\n      stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400\n      cells/mm3. This study also examines how the body handles Viracept when given with d4T and\n      3TC."
        }, 
        "brief_title": "A Study of Viracept in HIV-Positive Women", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 T cell count <= 400 cells/mm3.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior therapy or less than 1 month of therapy with d4T and/or 3TC.\n\n          -  Prior protease inhibitor therapy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002171", 
            "org_study_id": "259D", 
            "secondary_id": [
                "Study 534", 
                "AG1343 - 534"
            ]
        }, 
        "intervention": {
            "intervention_name": "Nelfinavir mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Nelfinavir"
            ]
        }, 
        "keyword": [
            "Placebos", 
            "Drug Therapy, Combination", 
            "Stavudine", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "Nelfinavir", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Univ of Southern California / LA County USC Med Cntr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "HIV Outpatient Clinics / LA State Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77009"
                    }, 
                    "name": "Baylor Univ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002171"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agouron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "Baylor Univ": "29.76 -95.369", 
        "HIV Outpatient Clinics / LA State Univ Med Ctr": "29.951 -90.072", 
        "Univ of Alabama at Birmingham": "33.521 -86.802", 
        "Univ of Southern California / LA County USC Med Cntr": "34.052 -118.244"
    }
}